Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study

Abstract

Imiquimod 5% cream did not show safety concerns and is suitable for use in HIV+ subjects with anogenital warts and successful HAART treatment.

Pharmacotherapy of Basal Cell Carcinoma, Anogenital Warts, and Actinic Keratoses: Focus on Topical Imiquimod

“…45 There have been several studies demonstrating the efficacy of imiquimod in patients infected with human immunodeficiency virus (HIV), a population in whom rates of EGW are higher than their immunocompetent cohorts. [46][47][48][49][50][51] Safety and efficacy of imiquimod in immunocompromised patients with EGW was studied by Conant et al 46 Successful treatment was defined as achieving a .50% reduction in wart area, which occurred in 38% of patients treated with imiquimod versus 14% for vehicle, a statistically significant difference. 46 An open-label study of EGW in HIV-positive patients concurrently treated with highly active antiretroviral therapy (HAART) and imiquimod 5% cream demonstrated a total clearance of EGW of 50% in successfully-treated patients.…”

Azacitidine: A new medication associated with Sweet syndrome

“…1 A 69-year-old man presented with a fever and a painful vesicular patch at the site of subcutaneous azacitidine injection (Fig 1, A).…”

“…Particularly susceptible are those with uncontrolled diabetes, organ transplantation, or hematologic malignancy. 1 The disease is characterized by angioinvasion with soft tissue destruction and may be rapidly progressive and fatal, with overall mortality exceeding 65%. 1 Mucormycosis manifests in one of five clinical forms: rhinocerebral, pulmonary, gastrointestinal, cutaneous, or disseminated disease.…”

“…1 The disease is characterized by angioinvasion with soft tissue destruction and may be rapidly progressive and fatal, with overall mortality exceeding 65%. 1 Mucormycosis manifests in one of five clinical forms: rhinocerebral, pulmonary, gastrointestinal, cutaneous, or disseminated disease. 1 The primary cutaneous variant is rare and typically presents as a single necrotic hemorrhagic ulcer following percutaneous inoculation of fungal spores.…”

“…1 Mucormycosis manifests in one of five clinical forms: rhinocerebral, pulmonary, gastrointestinal, cutaneous, or disseminated disease. 1 The primary cutaneous variant is rare and typically presents as a single necrotic hemorrhagic ulcer following percutaneous inoculation of fungal spores. 2 We present a case of superficial noncontiguous primary mucormycosis attributed to insulin injections in a normoglycemic type 2 diabetic in the absence of additional immunosuppression.…”